Janet B. McGill, MD, MA, FACE
Professor of Medicine
- Phone: 314-362-8681
- Fax: 314-0362-4833
- Email: email@example.com
Dr. McGill completed her internship, residency and was chief resident at William Beaumont Hospital in Royal Oak Michigan. After her fellowship in Endocrinology at Washington University, she joined the faculty in 1987. She has been an active clinical researcher in diabetes for over 25 years, and continues to test new therapies for diabetes and novel approaches to type 1 and type 2 diabetes. Currently, Dr. McGill is the principal investigator (PI) or sub-investigator on more than 10 clinical trials investigating new treatments for diabetes and its complications. She has served on steering and safety committees for multi-centered clinical trials, including RENAAL, TREAT, FOCAL, KEEP and the SUN studies in diabetic nephropathy; and currently serves on planning committees and data safety monitoring boards for a number of ongoing national and international clinical trials. She is a member of the board of directors for the American Association of Clinical Endocrinologists, and the AACE Diabetes Scientific Committee that recently published updated guidelines for the care of persons with type 2 diabetes.
Dr. McGill directs the Fellowship in Endocrinology, Diabetes and Metabolism and has a busy practice at the Center for Advanced Medicine treating patients with diabetes, thyroid disease and other endocrine problems.
Diabetes affects 12% of the US population, and has devastating long term effects that both shorten life and greatly alter the quality of life. The treatment of diabetes has improved with the advent of newer therapies that target multiple metabolic pathways. Nonetheless, patients often face severe consequences of vision loss, end stage kidney disease, cardiovascular disease and are at increased risk for depression. Dr. McGill and her staff, along with colleagues in the Division of Endocrinology, Metabolism and Lipid Research, conduct numerous clinical trials in type 1 diabetes, type 2 diabetes, hyperlipidemia and vitamin D deficiency. The largest of these is the Glycemia Reduction Approaches for Diabetes: A Comparative Effectiveness Study (GRADE study), which hopes to enroll 150 subjects with type 2 diabetes over 2 years. Persons with diabetes will take one of four medications that are currently on the market. The study will last 5-7 years, and participants will have all diabetes medications, testing supplies and laboratory tests covered for the duration of the study. Other studies are testing novel approaches to the reduction of vascular disease by augmenting vitamin D, and by reducing inflammation.
Dr. McGill’s research staff includes four nurses, an administrator, a dietitian and medical assistants who have years of experience doing both investigator-initiated and multi-centered clinical trials.
Awards and Honors
Best Doctor, 1998-2013
America’s Top Doctor 2007-2013
Named Best Doctor in Women’s Health, 2008